Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: Diagnostic and prognostic implications

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 4, 2012, Pages 375-384

  Evangelista, L ^a   Baretta, Z ^a   Vinante, L ^a   Bezzon, E ^a   De Carolis, V ^a   Cervino, A R ^a   Gregianin, M ^a   Ghiotto, C ^a   Saladini, G ^a   Pomerri, F ^a   Muzzio, P C ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Breast neoplasms; Follow up studies; Positron emission tomography and computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RADIODIAGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ITALY; MIDDLE AGED; PREVALENCE; REPRODUCIBILITY; RISK FACTOR; STATISTICS; TUMOR RECURRENCE;

BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84869746187     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ries LAG, Harkins D, Krapcho M et al. SEER Cancer Statics Review, 1975-1975. Bethesda, MD: National Cancer Institute [Internet]. [cited 2012 May 3]. Available at: http//seer.cancer.gov/csr/1975_2003/
2. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG et al. American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. J Clin Oncol 2006; 24:1-7
3. Bombardieri E, Alessi A, Pallotti F, Serafini G, Mazzucca N, Seregni E et al. FDG-PET and tumour markers test for the diagnosis of breast cancer. In: Bombardieri E, Bonadonna G, Gianni L, editors. Breast cancer. Heidelberg: Desk Editor; 2008. p. 189-200.
4. Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM et al. Integrated Positron Emission Tomography/Computed Tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010;28:3154-9.
5. 18F] fluoro-2-deoxy-D-glucose. J Comp Assist Tomo 1993;17:582-9.
6. Hamblen SM, Lowe VJ. Clinical 18F-FDG oncology patient preparation techniques. J Nucl Med Technol 2003;29:1393-8.
7. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:4357-68. (Pubitemid 41185156)
8. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290:3199-206. (Pubitemid 38020681)
9. Cox DR. Regression models and life table. J R Stat Soc B 1972;34:187-220.
10. Harrell FE, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modeling strategies for improvement prognostic prediction. Stats Med 1984;3:143-52. (Pubitemid 14052973)
11. van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomized trial (EORTC 10801 and DBCG-82TM). EORTC breast cancer cooperative group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 1999;35:32-8. (Pubitemid 29079488)
12. Aukema TS, Russell NS, Wesseling J, Rutgers EJ. Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: lasting local control and acceptable morbidity. Eur J Surg Oncol 2009;35:469-74
13. Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D et al. Prognosis following salvage mastectomy for recurrence in the breast conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1993;11:44-8. (Pubitemid 23059973)
14. Clark GM, Sledge Jr GW, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1987;5:55-61. (Pubitemid 17007856)
15. Hicks RJ, Ware RE, Lau EWF. PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging 2006;6:S52-S62.
16. Grunfeld E, Mant D, Yudkin P, Dalton RA, Cole D, Stewart J et al. Routine follow-up for breast cancer in primary care: randomized trial. BMJ 1996;13:665-9.
17. Hathaway PB, Mankoff DA, Maravioklla KP, Austin-Seymour MM, Ellis GK, Gralow JR et al. Value of combined FDG PET and MRI imaging in the evaluation of suspected recurrent local regional breast cancer: preliminary experience. Radiology 1999;210:807-14. (Pubitemid 29124045)
18. Weir L, Worsley D, Bernstein V. The value of FDG Positron Emission Tomography in the Management of Patients with Breast Cancer. Breast Journal 2005;3:204-9. (Pubitemid 40664065)
19. Grassetto G, Fornasiero A, Otello D, Bonciarelli G, Rossi E, Nashimben O et al. (18)F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging, a multicentre study. Eur J Radiol 2010 [Epub ahead of print].
20. Champion L, Brain E, Giraudet AL, Le Stanc E, Wartski M, Edeline V et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer 2010 [Epub ahead of print].
21. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, PET Study Group: Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22:277-85. (Pubitemid 41095092)
22. Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanlet TJ et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516-23. (Pubitemid 32730089)
23. Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK, Dunnwald LK et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 2002;22:5-17.
24. Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004;27:407-10. (Pubitemid 39045254)
25. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18F-FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-9. (Pubitemid 28481635)
26. Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005;19:573-9. (Pubitemid 43161842)
27. Keloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-808. (Pubitemid 40525178)
28. Veith-hainbach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EAM et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007;80:508-15. (Pubitemid 47343078)
29. Piperkova E, Raphael B, Altinyay ME, Castellon I, Libes R, Sandella N et al. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med 2007;32:429-34. (Pubitemid 46791460)
30. Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 2010;14:1-103.
31. Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J et al. Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients. J Nucl Med 2002;43:325-9. (Pubitemid 34208093)
32. Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW. Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res 2008;10:R83.